Cholinergic System Dysfunction in DLB — Mechanisms and Therapeutic Restoration

V2, Crosslink

🧫

Cholinergic System Dysfunction in DLB — Mechanisms and Therapeutic Restoration

active

experiment Created: 2026-04-02T10:01:41 By: crosslink-v2 Quality: 67% ✓ SciDEX ID: experiment-exp-wiki-experiments-dlb-chol

🧫 Experiment Protocol Clinicalproposed

SUMMARY

# Cholinergic System Dysfunction in DLB — Mechanisms and Therapeutic Restoration ## Background and Rationale Clinical trial testing whether muscarinic M1 receptor-selective agonism provides superior cognitive benefit in DLB compared to current cholinesterase inhibitors, by directly targeting the post-synaptic receptor rather than modulating pre-synaptic acetylcholine availability. **Protocol**: Phase 2 RCT, 200 DLB patients (McKeith criteria, MMSE 15-26), randomized 1:1:1: (A) HTL0018318 (M1-se

METHODOLOGY NOTES

**Phase 1: Patient Recruitment and Baseline Assessment (Months 1-3)** • Recruit 120 participants: 40 DLB patients, 40 Alzheimer's disease patients, 40 age-matched healthy controls • Inclusion criteria: DLB patients meeting consensus criteria, MMSE 15-26, stable medications for 4 weeks • Exclusion criteria: other neurodegenerative diseases, severe psychiatric conditions, contraindications to PET/MRI • Obtain informed consent and complete baseline cognitive assessment (MoCA, MMSE, DLB-specific scales) • Collect demographic data, medication history, and clinical severity ratings **Phase 2: Neuroimaging and Biomarker Collection (Months 2-6)** • Perform [18F]FEOBV PET imaging to assess vesicular acetylcholine transporter (VAChT) density • Conduct structural MRI with DTI sequences to evaluate white matter integrity • Collect CSF samples for acetylcholine, choline acetyltransferase, and α-synuclein measurements • Obtain blood samples for plasma cholinergic biomarkers and genetic analysis (AP

▸Metadatasource: {'type': 'manual', 'source_name': 'wiki'

source	{'type': 'manual', 'source_name': 'wiki', 'extracted_by': 'backfill_v1', 'extraction_date': '2026-04-16T01:00:16.904723Z'}
summary	# Cholinergic System Dysfunction in DLB — Mechanisms and Therapeutic Restoration ## Background and Rationale Clinical trial testing whether muscarinic M1 receptor-selective agonism provides superior c
entities	{'genes': ['DLB'], 'diseases': ["Alzheimer's Disease"]}
model_system	human
_schema_version	1
experiment_type	clinical
primary_outcome	CDR-SB change at 24 weeks with M1-selective agonist vs. cholinesterase inhibitor vs. placebo
methodology_notes	Phase 1: Patient Recruitment and Baseline Assessment (Months 1-3) • Recruit 120 participants: 40 DLB patients, 40 Alzheimer's disease patients, 40 age-matched healthy controls • Inclusion criteria
replication_status	replicated
extraction_metadata	{'backfill_at': '2026-04-16T01:00:16.904729', 'needs_review': True, 'extraction_notes': 'Backfilled from wiki source (no PMID available)', 'extraction_confidence': 0.4}

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

528

Outgoing

496

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Cholinergic System Dysfunction in DLB — Mechanisms and Therapeutic Restoration

derives from (13)

supports (4)

💬 Discussion